Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Subjects With Hyperlipidemia, Dyslipidemia Clear all
Completed Phase 3 Interventional

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

NCT00487994
View directory record Official record
Conditions
Dyslipidemia
Interventions
Lapaquistat acetate, Lapaquistat acetate and atorvastatin, Atorvastatin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Citrus Bioflavonoids/Vitamin E in Conjunction With Fish Oil Supplementation

NCT01671254
View directory record Official record
Conditions
Hyperlipidemia
Interventions
FishOil, CBE75, CBE150, placebo
Dietary Supplement
Lead sponsor
MetaProteomics LLC
Industry
Eligibility
18 Years to 72 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Gig Harbor, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Not applicable Interventional

Regeneron 1331 Kinetics Sub-Study HoFH

NCT04722068
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
Kinetics test
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional

The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)

NCT00076518
View directory record Official record
Conditions
HIV Infections, Hypertriglyceridemia
Interventions
Fenofibrate, Fish Oil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
5
States / cities
San Francisco, California • Atlanta, Georgia • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 6:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lipoprotein Interactions and Platelet Function in Healthy Individuals and Those With Lipid Disorders

NCT06747000
View directory record Official record
Conditions
Lipid Disorders
Interventions
Not listed
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
East Providence, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides

NCT00812955
View directory record Official record
Conditions
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
ABT-143, simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
129
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Jul 23, 2026, 6:16 AM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

NCT00532311
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and stable statin therapy, Stable statin therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia

NCT00474240
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin 20 mg, AEGR-733 5 mg, AEGR-733 10 mg, Placebo, AEGR-733 5 mg + atorvastatin 20 mg, AEGR-733 10 mg + atorvastatin 20 mg
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Huntsville, Alabama • Jacksonville, Florida • Ocala, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional

Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

NCT00137462
View directory record Official record
Conditions
Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
48
States / cities
Huntsville, Alabama • Union Grove, Alabama • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2007 · Synced Jul 23, 2026, 6:16 AM EDT
Not listed Phase 3 Interventional

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

NCT01229566
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
AKR-963
Drug
Lead sponsor
Trygg Pharma, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

NCT00134173
View directory record Official record
Conditions
Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
127
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 124 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Metformin on Blood Vessel Structure and Function

NCT00105066
View directory record Official record
Conditions
Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.

NCT00267254
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia, Hypercholesterolemia
Interventions
torcetrapib/atorvastatin, simvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2007 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

NCT01968954
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615;RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Not applicable Interventional

Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome

NCT01010841
View directory record Official record
Conditions
Metabolic Syndrome, Overweight, Obesity, Hypercholesterolemia
Interventions
UltraMealPlus 360 (Medical food), Low-glycemic-load diet
Dietary Supplement · Other
Lead sponsor
MetaProteomics LLC
Industry
Eligibility
20 Years to 75 Years · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

NCT05889156
View directory record Official record
Conditions
High Triglycerides
Interventions
NST-1024, Placebo
Drug · Other
Lead sponsor
NorthSea Therapeutics B.V.
Industry
Eligibility
18 Years to 79 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional

Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.

NCT00136981
View directory record Official record
Conditions
Hypercholesterolemia, Familial, Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
Hartford, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

NCT00484419
View directory record Official record
Conditions
Type 2 Diabetes, Hyperlipidemia
Interventions
Colesevelam HCl, rosiglitazone maleate, sitagliptin phosphate
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
La Mesa, California • Los Angeles, California • Los Gatos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

NCT05852431
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Pegozafermin, Placebo
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
22 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
73
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

NCT01163851
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
4 mg/kg, 0.5 mg/kg
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
5
States / cities
Peoria, Arizona • Phoenix, Arizona • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

NCT03593785
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
AZD8233
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

NCT02867813
View directory record Official record
Conditions
Dyslipidemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
5,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
144
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 136 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)

NCT02624869
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 17 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
The Bronx, New York • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Jul 23, 2026, 6:16 AM EDT